Publications by authors named "Ruchi Kudalkar"
Article Synopsis
- Multiple myeloma (MM) is a type of cancer involving abnormal plasma cells with various genetic changes that affect DNA repair and response mechanisms.
- These alterations allow cancers to grow, evolve, and resist treatment, often due to the malfunction of key genes like TP53 and TP73, which normally help manage damaged DNA.
- The review focuses on how these DNA damage response systems operate in healthy cells versus in MM, as well as discussing treatment strategies that leverage this knowledge for better patient outcomes.
In transplant-eligible patients who undergo upfront autologous stem cell transplant (ASCT) for multiple myeloma (MM), standard practice is to treat with six to eight cycles of induction therapy followed by high-dose chemotherapy with ASCT. A gap between the end of induction and the day of ASCT exists to allow stem cell mobilization and collection. Despite attempts to limit the length of this interval, we noticed that some patients experience interval progression (IP) of disease between the end of induction therapy and the day of ASCT.
View Article and Find Full Text PDF